NCT05855083Phase 2Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Study sponsor: Omeros Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12Estimated
Enrollment · participants18Estimated
Source updated2025-03-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.